Antibiotics overuse in livestock supply chains
Antibiotics use in livestock is a leading cause of rising antimicrobial resistance (AMR) in humans. The food industry is the largest consumer of antibiotics globally, and uses antibiotic drugs to prevent disease or promote growth in healthy farm animals rather than treat clinically ill animals.
AMR and antibiotics misuse presents a systemic risk to investor portfolios, including within the food, pharmaceutical, healthcare and insurance industries.
The UK government described the over-use of antibiotics as “excessive and inappropriate” in a report which found that drug-resistant infections could cost the world around US $100 trillion in lost output by 2050 – a cost that will come home to roost in a widely diversified portfolio.
FAIRR’s collaborative investor engagement on antibiotics is supported by more than 70 institutional investors representing nearly $5 trillion in AUM. The engagement asks 20 global food companies to limit antibiotic use in their supply chains to protect public health and long-term value creation by:
- Establishing an antibiotics policy to phase out routine, prophylactic use across all supply chains.
- Specifying clear targets and timelines for implementation.
- Increasing transparency by reporting on implementation and data verification.
For an investor progress update see our investor briefing , Responding to Resistance, which gives an overview on how this issue is evolving and provides a progress update on our collaborative engagement with 20 global fast-food and restaurant companies.
- Bloomin’ Brands
- Brinker International
- The Cheesecake Factory
- Darden Restaurants
- Domino’s Pizza Group
- Greene King
- Marston’s plc
- Mitchells & Butlers
- Restaurant Brands Intl
- Papa John’s
- Sonic Corporation
- Texas Roadhouse
- The Restaurant Group
- The Wendy’s Company
- JD Wetherspoon
- Whitebread plc
- Yum! Brands
The antibiotics engagement is open to all FAIRR members. There is no cost to joining FAIRR, and member investors benefit from:
- Issue expertise, best practice guidance and cutting-edge research focused on the risks and opportunities in animal protein production.
- Exclusive company-level analysis.
- Access to a growing global network of investors.
- Facilitated engagements that allow investors to have direct dialogues with companies supported by progress reports and impact assessments for the duration of the engagement.
- A range of interactive events including panel and roundtable discussions offering multiple opportunities for learning, information-sharing and networking.